Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy ResultsMarketBeat · 2 days ago
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy TranscriptSeeking Alpha · 2 days ago
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of MedicineGlobeNewsWire · 2 days ago
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference WebcastGlobeNewsWire · 4 days ago
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026GlobeNewsWire · Oct 2, 2026Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$1.58 | -$1.52 | Beat |
| May 7, 2026 | -$1.33 | -$1.69 | Miss |
| Feb 26, 2026 | -$1.34 | -$1.39 | Miss |
| Nov 5, 2025 | -$1.20 | -$1.26 | Miss |
| Aug 5, 2025 | -$0.82 | -$1.20 | Miss |
| May 6, 2025 | -$0.75 | -$0.81 | Miss |